Pfizer Ltd vs Sai Parenterals Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: May 11, 2026

Key Highlights

The Latest Trading Price of Pfizer Ltd is ₹ 4811 as of 08 May 15:30 . The P/E Ratio of Pfizer Ltd is 0 as of March 2023 .The P/E Ratio of Sai Parenterals Ltd is 0 as of March 2023 . The Market Cap of Pfizer Ltd is ₹ 0 crore as of March 2023 .The Market Cap of Sai Parenterals Ltd is ₹ 0 crore as of March 2023 . The revenue of Pfizer Ltd for the Dec '25 is ₹ 683.24 crore as compare to the Sep '25 revenue of ₹ 684.19 crore. This represent the decline of -0.14% The revenue of Sai Parenterals Ltd for the Dec '25 is ₹ 0 crore as compare to the Sep '25 revenue of ₹ 0 crore. This represent the decline of 0% The ebitda of Pfizer Ltd for the Dec '25 is ₹ 208.2 crore as compare to the Sep '25 ebitda of ₹ 271.78 crore. This represent the decline of -23.39% The ebitda of Sai Parenterals Ltd for the Dec '25 is ₹ 0 crore as compare to the Sep '25 ebitda of ₹ 0 crore. This represent the decline of 0% The net profit of Pfizer Ltd changed from ₹ 150.71 crore to ₹ 141.84 crore over 7 quarters. This represents a CAGR of -3.41% The net profit of Sai Parenterals Ltd changed from ₹ 0 crore to ₹ 0 crore over 7 quarters. This represents a CAGR of 0.0% The Dividend Payout of Pfizer Ltd changed from 32.18 % on March 2021 to 98.34 % on March 2025 . This represents a CAGR of 25.03% over 5 yearsThe Dividend Payout of Sai Parenterals Ltd changed from 0 % on March 2021 to 0 % on March 2025 . This represents a CAGR of 0.0% over 5 years .

About Pfizer Ltd

Pfizer Limited is engaged in manufacturing, marketing, trading and export of pharmaceutical products.
The Company offer a portfolio of 150 specialised medicines in 15 therapeutic areas across 4 business categories.
It has its own manufacturing facility at Goa and Thane.
It has the distinction of being the first pharmaceutical company in India to start clinical research.
The Company sells products in nearly 185 countries having 43 manufacturing sites globally.

About Sai Parenterals Ltd

Sai Parenteral's Limited was originally incorporated as Sai Parenteral's Private Limited', a Private Limited Company on January 12, 2001, with the Registrar of Companies, at Hyderabad.
Thereafter, Company was converted into a Public Limited Company and the name of Company was changed to Sai Parenteral's Limited' w.e.f January 17, 2022. Sai Parenteral's is a diversified pharmaceutical formulations company engaged in the business of Branded Generic Formulations and Contract Development and Manufacturing Organization (CDMO) products and services for the domestic and international markets.
Company has developed a comprehensive and diversified portfolio of complex pharmaceutical products, covering both high-value and high-volume categories addressing critical therapeutic needs across the multiple disease areas.

FAQs for the comparison of Pfizer Ltd and Sai Parenterals Ltd

Which company has a larger market capitalization, Pfizer Ltd or Sai Parenterals Ltd?

Market cap of Pfizer Ltd is 22,009 Cr while Market cap of Sai Parenterals Ltd is 2,163 Cr

What are the key factors driving the stock performance of Pfizer Ltd and Sai Parenterals Ltd?

The stock performance of Pfizer Ltd and Sai Parenterals Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Pfizer Ltd and Sai Parenterals Ltd?

As of May 11, 2026, the Pfizer Ltd stock price is INR ₹4811.05. On the other hand, Sai Parenterals Ltd stock price is INR ₹489.7.

How do dividend payouts of Pfizer Ltd and Sai Parenterals Ltd compare?

To compare the dividend payouts of Pfizer Ltd and Sai Parenterals Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.